Zobrazeno 1 - 10
of 17
pro vyhledávání: '"S. N. Kizhlo"'
Autor:
D. A. Gusev, K. V. Zhdanov, K. V. Kozlov, T. N. Vinogradova, M. Yu. Kopot, V. S. Sukachev, S. S. Zhabrov, S. N. Kizhlo, S. Yu. Romanova, V. B. Musatov, N. V. Tyurenkova, Yu. A. Vlasova, E. Yu. Kolpashchikova, P. N. Fedorov, P. V. Minin, T. S. Korneeva
Publikováno v:
Журнал инфектологии, Vol 14, Iss 5, Pp 60-68 (2023)
The aim of the analysis was to describe the results of administration of pan-genotype antiviral therapy (glecaprevir / pibrentasvir, GLE / PIB) in real-world setting in three clinical centers in St. Petersburg within the city program for the treatmen
Externí odkaz:
https://doaj.org/article/6bca810fbc6e4594b9f661b807d84ac9
Autor:
N. V. Dunaeva, E. Yu. Kolpashchikova, S. Yu. Romanova, S. N. Kizhlo, S. V. Lapin, D. A. Gusev
Publikováno v:
Журнал инфектологии, Vol 10, Iss 4, Pp 53-63 (2018)
The aim of the study was to evaluate clinical, immunologic and anti-viral efficacy of antiviral therapy (АVT) with drugs of the direct antiviral action (DAA) of the chronic hepatitis C (CHC) complicated with secondary mixed cryoglobulinemia in small
Externí odkaz:
https://doaj.org/article/a5cd7da3adef44e384fcdff6a7f4b9fe
Autor:
V. T. Ivashkin, M. V. Mayevskaya, D. T. Abdurakhmanov, I. G. Bakulin, N. I. Geyvandova, M. L. Zubkin, S. N. Kizhlo, A. V. Kuznetsova, I. B. Latysheva, N. A. Mamonova, V. G. Morozov, O. I. Sagalova, Ye. V. Esaulenko, Ye. O. Lyusina
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 27, Iss 6, Pp 52-62 (2018)
Introduction. The options of antiviral therapy (AVT) in the stages of severe liver fibrosis and cirrhosis (LC) as well as in the patients with comorbidities for the long time were limited to the standard therapy by pegilated interferon (peg-IFN) in c
Externí odkaz:
https://doaj.org/article/648fb9a0265848459515bd7b7ee40f58
Autor:
M. V. Mayevskaya, V. T. Ivashkin, O. O. Znoyko, Ye. A. Klimova, D. T. Abdurakhmanov, I. G. Bakulin, P. O. Bogomolov, E. Z. Burnevich, M. Yu. Galushko, N. I. Geyvandova, K. V. Zhdanov, Ye. V. Esaulenko, S. N. Kizhlo, D. Yu. Konstantinov, N. I. Mironova, V. G. Morozov, Ye. A. Strebkova, I. G. Nikitin, M. F. Osipenko, V. D. Pasechnikov, O. I. Sagalova, I. M. Khayertynova, V. P. Chulanov, A. A. Yakovlev, I. A. Vasyutin, Ye. P. Tarkhova, E. N. Krasavina, M. Yu. Samsonov
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 27, Iss 6, Pp 41-51 (2018)
Aim of investigation. To estimate efficacy and safety of narlaprevir (NVR) with ritonavir (RTV), pegilated interferon (peg-IFN) and ribavirin (RBV) at treatmentnaïve and earlier treated noncirrhotic patients with chronic hepatitis C caused by the 1s
Externí odkaz:
https://doaj.org/article/0686acb179664d0d893a6a2414c4957c
Autor:
O. O. Znoyko, M. V. Maevskaya, E. A. Klimova, S. L. Maksimov, S. N. Kizhlo, N. A. Petrochenkova, F. I. Nagimova, R. A. Ivanov, Yu. N. Linkova, T. V. Chernovskaya
Publikováno v:
Журнал инфектологии, Vol 5, Iss 1, Pp 83-90 (2014)
Algeron (cepeginterferon alfa-2b) is a new pegylated form of interferon alfa containing linear polyethylene glycol (molecular weight 20 kDa). Pharmacokinetic profile of Algeron allows once weekly administration. In phase II–III study 150 treatment-
Externí odkaz:
https://doaj.org/article/8309c85f05cb4ce69fe7e97dad55ad44
Autor:
Yu. V. Lobzin, K. V. Zhdanov, A. S. Simbirtsev, A. A. Yakovlev, S. N. Kizhlo, V. H. Fazilov, S. N. Zharov, M. F. Lebedev
Publikováno v:
Журнал инфектологии, Vol 4, Iss 4, Pp 80-89 (2014)
To assess the efficacy and safety of an experimental course of antiviral therapy with recombinant IL-1β in combination with recombinant interferon-α2b and ribavirin in patients with chronic hepatitis C infected with genotype 1 hepatitis C virus in
Externí odkaz:
https://doaj.org/article/e9cdfd986a8149cf8b5d4def697cb2d1
Autor:
M. V. Mayevskaya, O. O. Znoyko, Ye. A. Klimova, S. L. Maximov, S. N. Kizhlo, N. A. Petrochenkova, F. I. Nagimova, Yu. N. Linkova
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 24, Iss 2, Pp 53-64 (2014)
Aim of investigation. Comparative study of efficacy and safety of Algeron in dozes of 1,5 and 2,0 mkg/kg and PegIntron in combination to ribavirin within combined mode of treatment of patients with chronic hepatitis C (CHC) with subsequent assessment
Externí odkaz:
https://doaj.org/article/669a8954f13c48a996ee55f26090f58f
Autor:
D. T. Abrurakhmanov, V. G. Morozov, I. G. Nikitin, P. O. Bogomolov, N. I. Geyvandova, Ye. N. Bessonova, I. G. Bakulin, V. A. Isakov, K. V. Zhdanov, M. V. Mayevskaya, Ye. A. Nurmukhametova, E. Z. Burnevich, Ye. V. Chesnokov, V. D. Pasechnikov, A. Hill, I. Lonjon-Domanec, S. N. Kizhlo
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 24, Iss 1, Pp 39-46 (2014)
Aim of investigation. HEP3002 is the international early access program of efficacy and safety estimation of telaprevir in combination to peginterferon alpha and ribavirin for patients with severe fibrosis or liver cirrhosis caused by hepatitis C vir
Externí odkaz:
https://doaj.org/article/f727f4d5f8664bfcb7a762333d267e4a
Autor:
M. V. Mayevskaya, O. O. Znoyko, E. A. Klimova, S. L. Maximov, S. N. Kizhlo, N. A. Petrochenkova, F. I. Nagimova, R. A. Ivanov, Yu. N. Linkova, T. V. Chernovskaya
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 23, Iss 1, Pp 30-36 (2013)
Aim of the study. To compare efficacy and safety of Algeron 1.5 and 2.0 μg/kg with PegIntron in combination with ribavirin in the treatment of chronic hepatitis C and to determine therapeutic dose of Algeron.Materials and Methods. 150 adult treatmen
Externí odkaz:
https://doaj.org/article/ba56af4b112c4c51b8bd662454878759
Autor:
D.T. Abdurakhmanov, Igor G. Bakulin, V.I. Chervinko, M. B. Mayevskaya, S. N. Kizhlo, Mikhail L. Zubkin, O. I. Sagalova, Irina Kim, Vladimir Ivashkin
Publikováno v:
Clinical Medicine (Russian Journal). 96:820-825
Mixed cryoglobulinemia (MC) and cryoglobulinemic vasculitis (CV) are the most frequent extrahepatic manifestations in chronically infected hepatitis C virus (HCV) patients. Antiviral therapy with interferon and ribavirin used to play an important rol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::258091f8b02cbb17af801dc4a0cb2834
https://doi.org/10.18821/0023-2149-2018-96-9-820-825
https://doi.org/10.18821/0023-2149-2018-96-9-820-825